TrialCancer science2022

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.

Kan Yonemori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.